1993PubMedRequires access

Recombinant human granulocyte colony-stimulating factor: an overview.

G Koloc, K Scharnweber

Open publisher page 0 citations

Abstract

Recombinant granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor used for the reduction or prevention of cyclic neutropenia in cancer patients. Neutropenia is a major factor contributing to infection, morbidity, and mortality. Neutropenia also reduces the dosage of cytotoxic agents and often interrupts the course of treatment. The recent development of cloning G-CSF has been a major advancement in treating cyclic neutropenia. This article focuses on the mechanism of action, pharmacokinetics, and the clinical applications of G-CSF.

About this research paper

What this paper is about

Recombinant granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor used for the reduction or prevention of cyclic neutropenia in cancer patients. Neutropenia is a major factor contributing to infection, morbidity, and mortality. Neutropenia also reduces the dosage of cytotoxic agents and often interrupts the course of treatment. The recent development of cloning G-CSF has been a major advancement in treating cyclic neutropenia. This article focuses on the mechanism of action, pharmacokinetics, and the clinical applications of G-CSF.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Recombinant granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor used for the reduction or prevention of cyclic neutropenia in cancer patients. Neutropenia is a major factor contributing to infection, morbidity, and mortality. Neutropenia also reduces the dosage of cytotoxic agents and often interrupts the course of treatment. The recent development of cloning G-CSF has been a major advancement in treating cyclic neutropenia. This article focuses on the mechanism of action, pharmacokinetics, and the clinical applications of G-CSF.

Key concepts: Neutropenia, Medicine, Granulocyte colony-stimulating factor, Hematopoietic growth factor, Granulocyte, Cyclic neutropenia, Recombinant DNA, Haematopoiesis

Related papers

Back to paper searchBrowse research topicsOriginal source
Recombinant human granulocyte colony-stimulating factor: an overview. — Research Paper | ScholarLens